Loss of in vitro cytotoxicity of cisplatin after storage as stock solution in cell culture medium at various temperatures

Cancer

Volumn 79, Issue 9, 1997, Pages 1723-1728

  Schuldes, Horst ^a,b   Bade, Sven ^b   Knobloch, Jutta ^c   Jonas, Dietger ^a  

^a Klin F Urologie und Kinderurologie   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c Klin Johann Wolfgang Goethe U ^*

Author keywords

cisplatin; culture medium; cultured tumor cells; toxicity

Indexed keywords

CISPLATIN;

ARTICLE; BLADDER CARCINOMA; CANCER CELL CULTURE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY; DILUTION; DRUG POTENCY; DRUG SOLUTION; DRUG STABILITY; DRUG STORAGE; FLUOROMETRY; PRIORITY JOURNAL; TEMPERATURE;

EID: 0030977824     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19970501)79:9<1723::aid-cncr13>3.0.co;2-%23     Document Type: Article

References (13)

1. Niell HD, Webster KC, Smith EE. Anticancer drug activity in human bladder tumor cell lines. Cancer 1985; 56:1039-44.
2. Floyd JW, Lin G-Y, Proud GR. Multi-drug resistance of doxorubicin-resistant bladder cancer cell line. J Urol 1990; 144:169-71.
3. Rosenberg B, VanCamp L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumor agents. Nature 1969; 222:385-6.
4. Dietel M. What's new in cytostatic drug resistance and pathology. Pathol Res Pract 1991; 187:892-905.
5. Roberts JJ, Thompson AJ. The mechanism of action of antitumor platinum compounds. Prog Nucleic Acid Res Mol Biol 1979; 22:71-133.
6. Fraval HN, Rawlings CJ, Roberts JJ. Increased sensitivity of UV-repair-deficient human cells to DNA bound platinum products which unlike thymine dimers are not recognized by an endonuclease extracted from Micrococcus luteus. Mutat Res 1978; 51:121-32.
7. Meyn RE, Jenkins SF, Thompson LH. Defective removal of DNA cross-links in a repair-deficient mutant of Chinese hamster cells. Cancer Res 1982; 42:3106-10.
8. Sorenson CM, Eastman A. Influence of cis-diamminedichloroplatinum (II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells. Cancer Res 1988; 48:6703-7.
9. Kutscher B, Wulf J-P, Günther E. Cisplatin analogs in cancer therapy via cooperative corporate research. Bioforum 1995; 18:458-63.
10. Sternberg CN, Yagoda A, Scher HI, Watson RC, Herr HW, Morse MJ, et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 1988; 139:461-9.
11. Igawa M, Ohkuchi T, Ueki T, Ueda M, Okada K, Usui T. Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer. J Urol 1990; 144:662-5.
12. Buice RG, Soloway MS. Platinum kinetics in patients treated with cis-dichlorodiammine platinum (II). Ther Drug Monit 1982; 4:293-6.
13. Sfikakis PP, Souliotis VL, Katsilambros N, Markakis K, Vaiopoulos G, Tsokos GC, et al. Downregulation of interleukin-2 and alpha-chain interleukin-2 receptor biosynthesis by cisplatin in human peripheral lymphocytes, Clin lmmunol Immunopathol 1996; 79:43-9.